US20030040467A1
(en)
|
1998-06-15 |
2003-02-27 |
Mary Ann Pelleymounter |
Ig/ob fusions and uses thereof.
|
US6936439B2
(en)
|
1995-11-22 |
2005-08-30 |
Amgen Inc. |
OB fusion protein compositions and methods
|
US20030026779A1
(en)
*
|
1999-10-15 |
2003-02-06 |
Liming Yu |
Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc
|
US6114110A
(en)
*
|
1996-01-16 |
2000-09-05 |
University Of Michigan |
Isolation and propagation of a human herpesvirus derived from AIDS-associated Kaposi's sarcoma cells
|
US20050033033A1
(en)
*
|
1998-05-04 |
2005-02-10 |
Heinz Kohler |
Trans-membrane-antibody induced inhibition of apoptosis
|
US20030103984A1
(en)
*
|
1998-05-04 |
2003-06-05 |
Heinz Kohler |
Fusion proteins of biologically active peptides and antibodies
|
US7569674B2
(en)
*
|
1998-05-04 |
2009-08-04 |
Innexus Biotechnology International Limited |
Autophilic antibodies
|
US20040185039A1
(en)
*
|
2002-08-30 |
2004-09-23 |
Heinz Kohler |
Therapeutic applications of noncovalent dimerizing antibodies
|
DE69824039T2
(de)
|
1997-12-08 |
2005-08-18 |
Lexigen Pharmaceuticals Corp., Lexington |
Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
|
CA2315944A1
(en)
*
|
1997-12-24 |
1999-07-08 |
Diatech Pty. Ltd. |
Bifunctional molecules
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
EP1071468B1
(de)
*
|
1998-04-15 |
2006-06-14 |
Lexigen Pharmaceuticals Corp. |
Steigerung der antikörper-zytokin-fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor
|
US20090208418A1
(en)
*
|
2005-04-29 |
2009-08-20 |
Innexus Biotechnology Internaltional Ltd. |
Superantibody synthesis and use in detection, prevention and treatment of disease
|
EA005005B1
(ru)
*
|
1998-10-16 |
2004-10-28 |
Байоджен, Инк. |
ГИБРИДНЫЙ ПОЛИПЕПТИД β1α-ИНТЕРФЕРОНА ЧЕЛОВЕКА, ЕГО МУТАНТНЫЕ ФОРМЫ И ПРОИЗВОДНЫЕ И СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
|
CZ299164B6
(cs)
|
1998-10-16 |
2008-05-07 |
Biogen Idec Ma Inc. |
Farmaceutická kompozice obsahující glykosylovaný interferon-beta-1a navázaný na polymer
|
SI1121382T1
(sl)
*
|
1998-10-16 |
2007-02-28 |
Biogen Idec Inc |
Fuzijski proteini interferona-beta in uporabe
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US6913749B2
(en)
*
|
1998-11-02 |
2005-07-05 |
Resistentia Pharmaceuticals Ab |
Immunogenic polypeptides for inducing anti-self IgE responses
|
PL352332A1
(en)
*
|
1999-05-19 |
2003-08-11 |
Lexigen Pharm Corp |
Expression and export of interferon-alpha proteins as fc fusion proteins
|
DE60045931D1
(de)
|
1999-07-07 |
2011-06-16 |
Zymogenetics Inc |
Menschliches Rezeptor für Zytokine
|
AU782496B2
(en)
*
|
1999-07-13 |
2005-08-04 |
Bolder Biotechnology, Inc. |
Immunoglobulin fusion proteins
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
ATE316982T1
(de)
*
|
1999-08-09 |
2006-02-15 |
Lexigen Pharm Corp |
Mehrere zytokin-antikörper komplexen
|
CA2391080A1
(en)
|
1999-11-12 |
2001-05-25 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Erythropoietin forms with improved properties
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
WO2001053480A1
(en)
*
|
2000-01-24 |
2001-07-26 |
Sangamo Biosciences, Inc. |
Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules
|
CN1406249B
(zh)
|
2000-02-11 |
2010-06-16 |
默克专利股份有限公司 |
增加基于抗体的融合蛋白的循环半衰期
|
HUP0300868A3
(en)
*
|
2000-06-29 |
2005-11-28 |
Merck Patent Gmbh |
Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
|
US20020169290A1
(en)
*
|
2000-11-02 |
2002-11-14 |
Claus Bornaes |
New multimeric interferon beta polypeptides
|
EP1334128A2
(de)
*
|
2000-11-02 |
2003-08-13 |
Maxygen Aps |
Neue multimere interferon-beta-polypeptide
|
KR20030051897A
(ko)
*
|
2000-12-01 |
2003-06-25 |
다이버사 코포레이션 |
데할로게나제 활성을 가진 효소 및 이의 사용 방법
|
ES2649037T3
(es)
|
2000-12-12 |
2018-01-09 |
Medimmune, Llc |
Moléculas con semividas prolongadas, composiciones y usos de las mismas
|
US7141392B2
(en)
*
|
2001-01-09 |
2006-11-28 |
Queen Mary And Westfield College |
Latent fusion protein
|
TWI329129B
(en)
*
|
2001-02-08 |
2010-08-21 |
Wyeth Corp |
Modified and stabilized gdf propeptides and uses thereof
|
FR2821625B1
(fr)
*
|
2001-03-01 |
2003-05-16 |
Genodyssee |
Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
|
EP1370676A4
(de)
|
2001-03-02 |
2004-09-22 |
Zymogenetics Inc |
Cytokin-rezeptor aus maus
|
AU2002322478A1
(en)
*
|
2001-03-02 |
2002-12-16 |
Medimmune, Inc. |
Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
|
AU2002248571B2
(en)
*
|
2001-03-07 |
2007-01-18 |
Merck Patent Gmbh |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
CN1191271C
(zh)
*
|
2001-03-21 |
2005-03-02 |
中国科学院上海生物化学研究所 |
干扰素-胸腺肽融合蛋白及其制法
|
US6992174B2
(en)
*
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
FR2823220B1
(fr)
*
|
2001-04-04 |
2003-12-12 |
Genodyssee |
Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
|
HUP0400284A3
(en)
|
2001-05-03 |
2012-09-28 |
Merck Patent Gmbh |
Recombinant tumor specific antibody and use thereof
|
US20020193569A1
(en)
*
|
2001-06-04 |
2002-12-19 |
Idec Pharmaceuticals Corporation |
Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
|
US20030059811A1
(en)
*
|
2001-06-14 |
2003-03-27 |
Hakim Djaballah |
Methods of screening for ligands of target molecules
|
US7094757B2
(en)
*
|
2001-06-22 |
2006-08-22 |
Roche Diagnostics Corporation |
Complexes comprising a prion protein and a peptidyl prolyl isomerase chaperone, and method for producing and using them
|
ATE522603T1
(de)
*
|
2001-06-22 |
2011-09-15 |
Hoffmann La Roche |
Löslicher komplex, der retrovirale oberflächen- glykoproteine und fkpa oder slyd enthält
|
US6962982B2
(en)
*
|
2001-06-22 |
2005-11-08 |
Roche Diagnostics Corporation |
Soluble complexes of target proteins and peptidyl prolyl isomerase chaperones and methods of making and using them
|
EP1411880B1
(de)
*
|
2001-07-11 |
2018-04-25 |
University of Miami |
Rekombinante vsv zur behandlung von tumorzellen
|
US20030104604A1
(en)
*
|
2001-08-03 |
2003-06-05 |
Weiping Yang |
Genetically engineered bacterial strains for the display of foreign peptides on filamentous phage
|
CN1405181A
(zh)
*
|
2001-08-10 |
2003-03-26 |
中国人民解放军军事医学科学院生物工程研究所 |
血清白蛋白与干扰素的融合蛋白
|
US6900292B2
(en)
*
|
2001-08-17 |
2005-05-31 |
Lee-Hwei K. Sun |
Fc fusion proteins of human erythropoietin with increased biological activities
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
US6797493B2
(en)
*
|
2001-10-01 |
2004-09-28 |
Lee-Hwei K. Sun |
Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
|
US7186804B2
(en)
*
|
2001-12-04 |
2007-03-06 |
Emd Lexigen Research Center Corp. |
IL-2 fusion proteins with modulated selectivity
|
US7572763B2
(en)
*
|
2002-02-21 |
2009-08-11 |
Wyeth |
Follistatin domain containing proteins
|
AU2003217612A1
(en)
*
|
2002-02-21 |
2003-09-09 |
Wyeth |
GASP1: a follistatin domain containing protein
|
US20080108560A1
(en)
*
|
2002-03-05 |
2008-05-08 |
Eli Lilly And Company |
Heterologous G-Csf Fusion Proteins
|
US20040063912A1
(en)
*
|
2002-03-15 |
2004-04-01 |
The Brigham And Women's Hospital, Inc. |
Central airway administration for systemic delivery of therapeutics
|
JP4883665B2
(ja)
*
|
2002-07-17 |
2012-02-22 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
インターフェロン−βを使用する腎不全のための治療法
|
CA2497628A1
(en)
*
|
2002-09-05 |
2004-03-18 |
Medimmune, Inc. |
Methods of preventing or treating cell malignancies by administering cd2 antagonists
|
JP4547561B2
(ja)
*
|
2002-09-16 |
2010-09-22 |
ザ ジョンズ ホプキンス ユニバーシティー |
メタロプロテアーゼによるミオスタチンの活性化、およびミオスタチン活性の調節法
|
ATE502051T1
(de)
|
2002-10-16 |
2011-04-15 |
Purdue Pharma Lp |
Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung
|
US7261893B2
(en)
*
|
2002-10-22 |
2007-08-28 |
Wyeth |
Neutralizing antibodies against GDF-8 and uses therefor
|
US20040223966A1
(en)
*
|
2002-10-25 |
2004-11-11 |
Wolfman Neil M. |
ActRIIB fusion polypeptides and uses therefor
|
DK1572748T3
(da)
*
|
2002-12-17 |
2010-08-23 |
Merck Patent Gmbh |
Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
|
BRPI0407533A
(pt)
*
|
2003-02-18 |
2006-02-14 |
Merck Patent Ges Mit Beschaenk |
proteìnas de fusão e muteìnas do interferon alfa com propriedades melhoradas
|
WO2004091653A1
(en)
*
|
2003-04-17 |
2004-10-28 |
Ares Trading S.A. |
Interferon beta in severe acute respiratory syndrome (sars)
|
CN1535724B
(zh)
*
|
2003-04-23 |
2012-09-05 |
北京金迪克生物技术研究所 |
重组人干扰素在制备预防严重性急性呼吸道综合征的药物的用途
|
DE602004031390D1
(de)
*
|
2003-05-06 |
2011-03-24 |
Syntonix Pharmaceuticals Inc |
Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
CA2522690A1
(en)
*
|
2003-05-06 |
2004-11-25 |
Syntonix Pharmaceuticals, Inc. |
Inhibition of drug binding to serum albumin
|
US7348004B2
(en)
*
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
US20070161087A1
(en)
*
|
2003-05-29 |
2007-07-12 |
Wolfgang Glaesner |
Glp-1 fusion proteins
|
EP1635870A2
(de)
*
|
2003-06-02 |
2006-03-22 |
Wyeth |
Verwendung von myostatin (gdf8) inhibitoren in kombination mit kortikosteroiden zur behandlung neuromuskulärer erkrankungen
|
KR100758755B1
(ko)
*
|
2003-06-12 |
2007-09-14 |
일라이 릴리 앤드 캄파니 |
Glp-1 유사체 융합 단백질
|
US20050069521A1
(en)
*
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
KR20050047030A
(ko)
|
2003-11-13 |
2005-05-19 |
한미약품 주식회사 |
약물의 캐리어로서 유용한 IgG Fc 단편 및 그의제조방법
|
WO2005063820A2
(en)
|
2003-12-30 |
2005-07-14 |
Merck Patent Gmbh |
Il-7 fusion proteins
|
AU2004309063B2
(en)
*
|
2003-12-31 |
2010-10-28 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
PT1706428E
(pt)
*
|
2004-01-22 |
2009-12-29 |
Merck Patent Gmbh |
Anticorpos anticancerígenos com fixação de complemento reduzida
|
WO2005074546A2
(en)
*
|
2004-02-02 |
2005-08-18 |
Ambrx, Inc. |
Modified human growth hormone polypeptides and their uses
|
US7670595B2
(en)
*
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
CA2575563A1
(en)
*
|
2004-08-12 |
2006-02-23 |
Wyeth |
Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
|
US20090249503A1
(en)
*
|
2004-12-06 |
2009-10-01 |
Bolder Biotechnology, Inc. |
Enzyme conjugates for use as detoxifying agents
|
CA2591297C
(en)
*
|
2004-12-09 |
2015-01-13 |
Stephen D. Gillies |
Il-7 variants with reduced immunogenicity
|
EP2192132A3
(de)
|
2005-02-08 |
2010-08-18 |
ZymoGenetics, Inc. |
Anti-il-20-, Anti-il-22- und Anti-il-22ra-Antikörper und Bindungspartner sowie Verwendungsverfahren bei Entzündungen
|
WO2006107611A2
(en)
*
|
2005-03-23 |
2006-10-12 |
Wyeth |
Detection of an immune response to gdf-8 modulating agents
|
KR100754667B1
(ko)
|
2005-04-08 |
2007-09-03 |
한미약품 주식회사 |
비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물
|
US20070054360A1
(en)
|
2005-05-12 |
2007-03-08 |
Zeren Gao |
Compositions and methods for modulating immune responses
|
EP1899368A2
(de)
*
|
2005-05-26 |
2008-03-19 |
Schering Corporation |
Interferon-igg-fusion
|
AU2006280587B2
(en)
*
|
2005-08-16 |
2011-02-24 |
Hanmi Science Co., Ltd. |
A method for the mass production of immunoglobulin Fc region deleted initial methionine residues
|
JP2009507003A
(ja)
|
2005-09-01 |
2009-02-19 |
アレス トレーディング ソシエテ アノニム |
視神経炎の治療
|
US20070104689A1
(en)
*
|
2005-09-27 |
2007-05-10 |
Merck Patent Gmbh |
Compositions and methods for treating tumors presenting survivin antigens
|
PT1966245E
(pt)
|
2005-12-30 |
2011-08-31 |
Merck Patent Gmbh |
Anticorpos anti-cd19 com imunogenicidade reduzida
|
ATE555125T1
(de)
|
2005-12-30 |
2012-05-15 |
Merck Patent Gmbh |
Interleukin-12p40-varianten mit verbesserter stabilität
|
US7625564B2
(en)
*
|
2006-01-27 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
|
AU2007244683A1
(en)
|
2006-04-27 |
2007-11-08 |
Pikamab, Inc. |
Methods and compositions for antibody therapy
|
WO2007135172A2
(en)
|
2006-05-24 |
2007-11-29 |
Laboratoires Serono S.A. |
Cladribine regimen for treating multiple sclerosis
|
AR061930A1
(es)
*
|
2006-07-18 |
2008-10-01 |
Centocor Inc |
Mimeticuerpos de glp-1 humanos, composiciones, metodos y usos
|
PL2292663T3
(pl)
|
2006-08-28 |
2014-03-31 |
Kyowa Hakko Kirin Co Ltd |
Antagonistyczne ludzkie przeciwciała monoklonalne swoiste wobec ludzkiego LIGHT
|
US20100143254A1
(en)
|
2006-10-16 |
2010-06-10 |
Medimmune, Llc |
Molecules with reduced half-lives, compositions and uses thereof
|
WO2008057529A2
(en)
*
|
2006-11-06 |
2008-05-15 |
Coley Pharmaceutical Group, Inc. |
Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp)
|
KR100888022B1
(ko)
|
2006-12-21 |
2009-03-09 |
재단법인 목암생명공학연구소 |
면역글로불린 Fc와 인간 아포리포단백질(a)크링글절편의 융합단백질 LK8Fc
|
EP2068923A4
(de)
|
2007-03-30 |
2010-11-24 |
Medimmune Llc |
Antikörper mit verminderten deamidierungsprofilen
|
US7625555B2
(en)
*
|
2007-06-18 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human interferon-like proteins
|
US8067548B2
(en)
*
|
2007-07-26 |
2011-11-29 |
Novagen Holding Corporation |
Fusion proteins having mutated immunoglobulin hinge region
|
JP5591701B2
(ja)
|
2007-09-21 |
2014-09-17 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
強力なアポトーシス活性および抗腫瘍活性を示すターゲティング化インターフェロン
|
AU2008308509B2
(en)
|
2007-10-04 |
2014-10-23 |
Zymogenetics, Inc. |
B7 family member zB7H6 and related compositions and methods
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
CN101918437B
(zh)
|
2007-11-21 |
2013-08-14 |
罗斯基勒大学 |
具有冰结合活性的多肽
|
CN101952309A
(zh)
*
|
2007-12-21 |
2011-01-19 |
Ifxa有限公司 |
蛋白酶抑制剂
|
MX2010008083A
(es)
*
|
2008-01-25 |
2010-12-20 |
Univ Aarhus |
Inhibicion de exositios selectivos de actividad papp-a contra igfbp-4.
|
CA2712606A1
(en)
|
2008-02-08 |
2009-08-13 |
Ambrx, Inc. |
Modified leptin polypeptides and their uses
|
RU2483081C2
(ru)
|
2008-07-23 |
2013-05-27 |
Ханми Сайенс Ко.,Лтд.,Kr |
Полипептидный комплекс, содержащий непептидильный полимер, обладающий тремя функциональными концами
|
CA2737146A1
(en)
|
2008-07-25 |
2010-01-28 |
The Regents Of The University Of Colorado |
Clip inhibitors and methods of modulating immune function
|
MX2011011044A
(es)
*
|
2009-04-22 |
2011-11-04 |
Merck Patent Gmbh |
Proteinas de fusion de anticuerpos con sitios de enlace de receptor fc neonatal (fcrn) modificados.
|
DK2437767T3
(en)
|
2009-06-01 |
2015-09-28 |
Medimmune Llc |
MOLECULES WITH EXTENDED half-lives and uses thereof
|
CA2769822C
(en)
|
2009-08-13 |
2019-02-19 |
The Johns Hopkins University |
Methods of modulating immune function
|
MX2012001882A
(es)
|
2009-08-13 |
2012-04-11 |
Crucell Holland Bv |
Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
EP2525787B1
(de)
|
2010-01-19 |
2017-03-15 |
Hanmi Science Co., Ltd. |
Flüssige formulierungen für ein g-csf-konjugat mit langzeitwirkung
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
KR101882523B1
(ko)
|
2010-03-26 |
2018-07-26 |
트러스티스 오브 다트마우스 칼리지 |
Vista 조절 t 세포 매개 단백질, vista 결합제 및 그것의 용도
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
US20110245469A1
(en)
*
|
2010-04-02 |
2011-10-06 |
Athena Discovery, Inc. |
Intermediates formed in biosynthesis of relaxin-fusion proteins with extended in vivo half-lives
|
AR080993A1
(es)
|
2010-04-02 |
2012-05-30 |
Hanmi Holdings Co Ltd |
Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
|
WO2011130533A1
(en)
|
2010-04-16 |
2011-10-20 |
Centocor Ortho Biotech Inc. |
Engineered plant cysteine proteases and their uses
|
SG10201505218YA
(en)
|
2010-07-09 |
2015-08-28 |
Biogen Hemophilia Inc |
Factor ix polypeptides and methods of use thereof
|
AU2011274472B2
(en)
|
2010-07-09 |
2017-03-30 |
Janssen Vaccines & Prevention B.V. |
Anti-human respiratory syncytial virus (RSV) antibodies and methods of use
|
CN102585013B
(zh)
*
|
2011-01-07 |
2014-04-23 |
中国人民解放军军事医学科学院生物工程研究所 |
一种含有ω干扰素的融合蛋白及制备方法
|
WO2012103165A2
(en)
|
2011-01-26 |
2012-08-02 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
CN102212139A
(zh)
*
|
2011-03-29 |
2011-10-12 |
中国人民解放军第二军医大学 |
森林脑炎病毒包膜E蛋白与人抗体Fc段融合蛋白及其用途
|
WO2013022328A1
(en)
*
|
2011-08-09 |
2013-02-14 |
Uab Profarma |
Derivatives of recombinant proteins, homo-multimers of granulocyte colony-stimulating factor and method of preparation thereof
|
EP2764565B1
(de)
|
2011-10-05 |
2023-02-22 |
OneD Material, Inc. |
Aktivmaterialien aus siliciumnanostrukturen für lithiumionenbatterien und verfahren dafür sowie zusammensetzungen, komponenten und entsprechende elemente damit
|
WO2013059885A2
(en)
|
2011-10-28 |
2013-05-02 |
Cephalon Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
TW201323442A
(zh)
|
2011-11-04 |
2013-06-16 |
Novartis Ag |
低密度脂蛋白相關蛋白6(lrp6)-半衰期延長構築體
|
CN105001340A
(zh)
*
|
2012-01-19 |
2015-10-28 |
施怀哲维克有限公司 |
动物融合重组型干扰素
|
TWI492952B
(zh)
*
|
2012-01-20 |
2015-07-21 |
Sbc Virbac Ltd |
動物融合重組型干擾素
|
EP2842969B1
(de)
|
2012-04-23 |
2018-03-14 |
NRL Pharma, Inc. |
Lactoferrinfusionsprotein und deren herstellungsmethode
|
CN103044554B
(zh)
*
|
2012-05-14 |
2014-08-27 |
旭华(上海)生物研发中心有限公司 |
重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
|
WO2013177231A1
(en)
|
2012-05-21 |
2013-11-28 |
Massachusetts Institute Of Technology |
Translocation of non-natural chemical entities through anthrax protective antigen pore
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
BR112014032276A2
(pt)
*
|
2012-06-22 |
2017-11-28 |
King S College London |
construtos de vista-ig e o uso de vista-ig para o tratamento de distúrbios autoimunes, alérgicos e inflamatórios
|
KR102268351B1
(ko)
|
2012-07-25 |
2021-06-22 |
셀덱스 쎄라퓨틱스, 인크. |
항-kit 항체 및 그의 용도
|
CN109793893B
(zh)
|
2012-09-07 |
2023-05-26 |
达特茅斯大学理事会 |
用于诊断和治疗癌症的vista调节剂
|
AU2013329311A1
(en)
|
2012-10-09 |
2015-04-30 |
Igenica Biotherapeutics, Inc. |
Anti-C16orf54 antibodies and methods of use thereof
|
WO2014089354A1
(en)
|
2012-12-07 |
2014-06-12 |
The Regents Of The University Of California |
Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
|
EP2941243A4
(de)
|
2013-01-04 |
2016-09-14 |
Massachusetts Inst Technology |
Oberflächenbindung bei der verabreichung eines arzneimittels auf nanopartikelbasis in ein gewebe
|
TWI745671B
(zh)
|
2013-03-15 |
2021-11-11 |
美商百歐維拉提夫治療公司 |
因子ix多肽調配物
|
CN110526971B
(zh)
|
2013-04-29 |
2023-06-30 |
泰华制药澳大利亚公司 |
抗-CD38抗体和与致弱干扰素α-2B的融合体
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
WO2014194100A1
(en)
|
2013-05-29 |
2014-12-04 |
The Regents Of The University Of California |
Anti-cspg4 fusions with interferon for the treatment of malignancy
|
AU2014274660B2
(en)
|
2013-06-06 |
2019-05-16 |
Pierre Fabre Médicament |
Anti-C10orf54 antibodies and uses thereof
|
WO2014202089A2
(en)
|
2013-06-18 |
2014-12-24 |
Roskilde Universitet |
Variants of anti-freeze polypeptides
|
AR096891A1
(es)
|
2013-07-12 |
2016-02-03 |
Hanmi Pharm Ind Co Ltd |
Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
|
WO2015053871A2
(en)
|
2013-08-26 |
2015-04-16 |
MabVax Therapeutics, Inc. |
NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa
|
PT3712174T
(pt)
|
2013-12-24 |
2022-05-27 |
Janssen Pharmaceutica Nv |
Anticorpos e fragmentos anti-vista
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
SI3097122T1
(sl)
|
2014-01-24 |
2020-07-31 |
Ngm Biopharmaceuticals, Inc. |
Protitelesa, ki se vežejo v domeni beta klotho 2, in metode za njihovo uporabo
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
US9738702B2
(en)
|
2014-03-14 |
2017-08-22 |
Janssen Biotech, Inc. |
Antibodies with improved half-life in ferrets
|
WO2015161832A1
(zh)
*
|
2014-04-25 |
2015-10-29 |
辅仁药业集团有限公司 |
长效重组人干扰素α2b-Fc融合蛋白
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
DK3143138T3
(da)
|
2014-05-13 |
2022-04-25 |
Bioatla Inc |
Betinget aktive biologiske proteiner
|
EP3142700B1
(de)
|
2014-05-16 |
2021-03-03 |
Medimmune, LLC |
Moleküle mit veränderter neonater fc-rezeptorbindung mit verbesserten therapeutischen und diagnostischen eigenschaften
|
HUE055189T2
(hu)
|
2014-06-04 |
2021-11-29 |
Biontech Res And Development Inc |
Humán monoklonális antitestek a GD2 ganglioziddal ellen
|
MX2016016310A
(es)
|
2014-06-11 |
2017-10-20 |
A Green Kathy |
Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
|
CN106795548A
(zh)
|
2014-09-03 |
2017-05-31 |
生物蛋白有限公司 |
在相同的真核细胞产生宿主中发现和产生条件活性生物蛋白
|
US10544199B2
(en)
|
2014-10-29 |
2020-01-28 |
Teva Pharmaceuticals Australia Pty Ltd |
Interferon alpha 2B variants
|
CN104403004B
(zh)
|
2014-11-24 |
2017-10-13 |
苏州丁孚靶点生物技术有限公司 |
抗体‑干扰素异二聚体的制备和用途
|
CN107405398A
(zh)
|
2014-12-05 |
2017-11-28 |
伊穆奈克斯特股份有限公司 |
鉴定vsig8作为推定vista受体及其用以产生vista/vsig8激动剂和拮抗剂的用途
|
DK3229838T3
(da)
|
2014-12-11 |
2020-10-19 |
Pf Medicament |
Anti-C10orf54-antistoffer og anvendelser deraf
|
CN114504652A
(zh)
|
2015-03-03 |
2022-05-17 |
科马布有限公司 |
抗体、用途和方法
|
KR20180002782A
(ko)
|
2015-05-06 |
2018-01-08 |
얀센 바이오테크 인코포레이티드 |
전립선 특이적 막 항원(psma) 이중특이성 결합제 및 그의 용도
|
DK3313882T3
(da)
|
2015-06-24 |
2020-05-11 |
Janssen Pharmaceutica Nv |
Anti-VISTA antistoffer og fragmenter
|
EP3341391A4
(de)
|
2015-08-27 |
2019-03-06 |
President and Fellows of Harvard College |
Zusammensetzungen und verfahren zur schmerzbehandlung
|
TW201718629A
(zh)
*
|
2015-09-25 |
2017-06-01 |
韓美藥品股份有限公司 |
包含多個生理多肽及免疫球蛋白Fc區之蛋白質接合物
|
KR20180054824A
(ko)
|
2015-09-29 |
2018-05-24 |
셀진 코포레이션 |
Pd-1 결합 단백질 및 이의 사용 방법
|
EP3371349A1
(de)
|
2015-11-02 |
2018-09-12 |
Bioatla, LLC |
Bedingt aktive polypeptide
|
MX2018009800A
(es)
|
2016-02-12 |
2018-11-09 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos.
|
AU2017250294B2
(en)
|
2016-04-15 |
2022-07-21 |
Immunext Inc. |
Anti-human VISTA antibodies and use thereof
|
US10766958B2
(en)
|
2016-09-19 |
2020-09-08 |
Celgene Corporation |
Methods of treating vitiligo using PD-1 binding antibodies
|
CN109952317A
(zh)
|
2016-09-19 |
2019-06-28 |
细胞基因公司 |
使用pd-1结合蛋白治疗免疫病症的方法
|
CA3080406A1
(en)
|
2016-10-28 |
2018-05-03 |
Nrl Pharma, Inc. |
Lactoferrin/albumin fusion protein and production method thereof
|
EP3534947A1
(de)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
|
EP3694889A1
(de)
|
2017-10-13 |
2020-08-19 |
Boehringer Ingelheim International GmbH |
Humane antikörper gegen thomsen-nouvelle (tn)-antigen
|
CN112740043A
(zh)
|
2018-07-20 |
2021-04-30 |
皮埃尔法布雷医药公司 |
Vista受体
|
US20210023236A1
(en)
*
|
2019-07-26 |
2021-01-28 |
Massachusetts Institute Of Technology |
Multi-targeted, tunable, sustained delivery of payloads to charged avascular tissues
|
WO2022147463A2
(en)
|
2020-12-31 |
2022-07-07 |
Alamar Biosciences, Inc. |
Binder molecules with high affinity and/ or specificity and methods of making and use thereof
|
EP4047016A1
(de)
|
2021-02-19 |
2022-08-24 |
Université de Strasbourg |
Anti-tenascin-c(tnc)-antikörper (nanobodies) mit einer einzigen domäne und deren verwendung
|
WO2023131901A1
(en)
|
2022-01-07 |
2023-07-13 |
Johnson & Johnson Enterprise Innovation Inc. |
Materials and methods of il-1beta binding proteins
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|